ロード中...
Successful Treatment of Pediatric Refractory/Relapsed AML with KIR-Ligand-Mismatched Cord Blood Transplant after FLAG-IDA Reinduction Therapy with or without the GO Regimen
Prognosis in pediatric patients with refractory/relapsed acute myeloid leukemia (AML) is grim, and there is no standard treatment for such patients. Combined treatment with intensive chemotherapy and gemtuzumab ozogamicin (GO), a monoclonal anti-CD33 antibody conjugated with calicheamicin, is useful...
保存先:
| 出版年: | Case Rep Hematol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Hindawi
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7037524/ https://ncbi.nlm.nih.gov/pubmed/32099697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/1378056 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|